Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NVLX-Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President of Nuvilex, stated, "The start of these studies at TD2 is a banner day for Nuvilex. We are extremely gratified to have a prestigious organization such as TD2 performing these studies on our behalf. It should be noted that these studies represent the first time that any work, either preclinical or clinical, has been done in the United States with the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology that has such exciting potential." Malignant ascites fluid in the abdomen contains cancer cells which can "seed" and form new tumors. Accumulation of this fluid is problematic for cancer patients and can cause significant discomfort. The current standard of care requires that malignant ascites fluid be removed from the abdomen of cancer patients at regular intervals.
In the studies being conducted by TD2, mice that have no immune system, and thus cannot reject foreign tissue from other species, will be injected with human ovarian cancer cells. These particular cells were chosen for these studies because: (i) they reproduce rapidly and form tumors; and (ii) the resultant tumors are proficient at producing malignant ascites fluid.
When the tumors have seeded in the abdomen, the mice will be randomized into four groups. One group of mice will be treated with Nuvilex's pancreatic cancer treatment consisting of the combination of Cell-in-a-Box(R) encapsulated live cells and the cancer prodrug ifosfamide (the encapsulated cells express an enzyme, CYP2B1, which converts ifosfamide into its cancer-killing form). A second group of mice will be treated with a drug normally used to treat ovarian cancer, and a third group will be administered that drug along with Nuvilex's Cell-in-a-Box(R) encapsulated live cells and ifosfamide combination. The remaining mice will serve as the "control" group for comparison purposes. The mice will be followed until humane endpoints have been reached. The time for this to occur for the treated mice will be compared to that for the control group of mice.
Nuvilex's CEO and President added, "We are confident that this work at TD2 will prove to be just the beginning of a long and fruitful journey for Nuvilex as we strive to develop our unique cancer treatment."
http://finance.yahoo.com/news/nuvilex-begins-preclinical-studies-translational-130000579.html
CONX-$0.3499 issued an 8K today....Under the terms of the Agreement, Corgenix (CONX) and Eli Lilly will work together to conduct a study to determine the feasibility of developing and manufacturing certain diagnostic test kits for the measurement of certain materials.
http://ih.advfn.com/p.php?pid=nmona&article=63317094&symbol=CONX
COCP- $0.345 current price. Director Phillip Frost purchased 111,200 shares of Cocrystal Pharma stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $0.29 per share, with a total value of $32,248.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission...that brings his total COCP holdings to 12,342,725 shares.
Thanks Joe, will add it to the radar
COCP- $0.32/share, Cocrystal
EXCERPT
One HCV (hepatitis C) company overlooked by the 12 SA articles already published on the Idenix/Merck deal is Cocrystal. Cocrystal's platform is based on x-ray crystallography. In one sentence, x-ray crystallography arranges large molecules in a repeating crystal lattice called a cocrsytal and then shoots x-rays at the cocrystal to take an atomic scale picture of the molecule. This picture is then used to map the molecule atom by atom and see how other molecules will fit into a weak spot in the molecule and attack it.
It should be clear how Cocrystal can use this system to synthesize antivirals. It finds highly conserved genes throughout all the genotypes of a given virus (in the case of HCV there are four main ones), maps that gene in an x-ray crystallograph atom by atom, and then synthesizes a molecule that will inhibit that gene.
This would seem like pie-in-the-sky science fiction, if not for the fact that heading the research team is Dr. Roger Kornberg, Nobel laureate in chemistry in 2006 for his work on x-ray crystallography of RNA polymerase, a transcription gene used by many viruses. Cocrystal is going after two genes in HCV: hepatitis C RNA dependent RNA polymerase, and RNA helicase, two genes the company sees as the biggest weak points in all genotypes of HCV.
Cocrystal is focusing on pursuing antivirals for three diseases. Besides HCV, it is also focusing on influenza and HRV, or human rhinovirus, AKA the common cold. Of these three, HCV is the most advanced, with preclinical testing nearly completed and the company planning to file an investigational new drug application in December (page 13), following which Phase 1 trials will begin. At that point we will find out the effectiveness of Cocrystal's research.
The influenza IND is planned for December 2015, and HRV only for December 2016. This is either because there is a lot more money and urgency in HCV, or because there are a lot less genotypes of HCV than there are of the flu or the cold. There are 99 known genotypes of HRV, and only 4 of HCV. It takes a lot more time to take and analyze x-ray crystallographs of 99 viruses than it does 4.
Cocrystal also has connections going for it as well. Followers of TEVA (NYSE:TEVA) Chairman and Opko Health (NYSE:OPK) investor Dr. Phillip Frost should be familiar with Cocrystal as the new incarnation of the corporate shell of BioZone, which was acquired by MusclePharm (OTCQB:MSLP) in January, which Frost is also invested in. Frost is behind the scenes here, so there is already a direct connection to Big Pharma in Teva. In fact, Teva funded Cocrystal's research back in 2011 to the tune of $7.5M (10-Q page 11)
Let's not forget as well that prior to being acquired by Gilead, Pharmasset had a relationship with the company through Emory University. (See 10-K linked above, page 18) Personal connections are doubtless important in big $11B deals, and will probably be a large factor in the next acquisition.
http://seekingalpha.com/article/2278853-speculators-on-the-next-hcv-acquisition-should-not-overlook-technological-platforms
NVLX - Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
SILVER SPRING, Md., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of Nuvilex's preclinical studies to be conducted by Translational Drug Development (TD2) in Scottsdale, Arizona.
The CEO and President of Nuvilex, Kenneth L. Waggoner, said, "In an effort to keep our shareholders informed on the very important preclinical studies to determine if Nuvilex's unique treatment of cancer can slow the accumulation of fluid in the abdomen, known as "malignant ascites," that is characteristic of the growth of many abdominal tumors, including pancreatic cancer, we wanted to announce that the encapsulated cells that will be used in the preclinical studies have arrived in the U.S. These are the encapsulated cells capable of converting the anticancer prodrug ifosfamide into its cancer-killing form using the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology. With the arrival of the encapsulated cells, the preclinical studies are now slated to begin at TD2 the week of August 18, 2014."
http://finance.yahoo.com/news/nuvilex-provides-status-preclinical-studies-130000563.html
Anyone know why this dropped from the $4 range...?
I like NVLX a lot - will be adding over the next few months...
There are many links out there concerning Nuvilex (NVLX) but this recent one describes the two activities of immediate interest: The Phase 2b trial for pancreatic cancer treatment and also a preclinical study for the symptoms associated with pancreatic cancer (that is imminent or has already started with Von Hoff at TD2)
http://online.wsj.com/article/PR-CO-20140714-905001.html
This is just a good site to get an overall broad brush feel for Nuvilex activities
http://www.stockmarketmediagroup.com/features/nvlx/
I think NVLX is quite a hidden gem with a lot of catalysts on several fronts. I anticipate high probability of great news and subsequent stock price appreciation in the very near term, IMO end of this calendar year and then first half of 2015 for news on the Phase 2b and the preclinical above. Good luck.
ACST Ph2 9/30 and a topline PK trial due 9/30
http://ih.advfn.com/p.php?pid=squote&symbol=acst
NVLX TY for the DD Joe - not previously familiar with the stock. Since biocatalyst does not carry it when is the 2b and do you have a link for it.
NVLX - 7/16/14 price about 27 cents. Nuvilex has a drug delivery technology which is innovative, effective, technologically advanced, causes less side effects, and is flexible across a broad spectrum of ailments. Nuvilex has Dr. Von Hoff and Dr. Matthias Löhr on their team, two leading pancreatic/tumor cancer specialists (google them). Nuvilex has the licensing agreements to patented technology (cell in a box). They have everything ready to capture major segments of this market (pancreatic cancer, pain, tumors, diabetes, etc). Investors right now are just early to the party, people are learning about Nuvilex as we speak...after pre-clinical (Aug 2014) and start of Phase 2b clinical (early 2015), the real show will start in my opinion.
VNRX.OB: market cap only around 27Mil. Its pineline includes diagnostics for colorectal cancers and Endometriosis (a progressive gynaecological condition that affects one in ten women of childbearing age)
Very low volume, probably because undiscovered.
Multi-Billion cancer diagnostics market:
http://seekingalpha.com/article/1980881-an-overview-of-the-multibillion-dollar-colorectal-cancer-diagnostics-market?source=yahoo
TheStreet called it "Bright Biotech" in its yesterday's article:
http://wallstcheatsheet.com/stocks/2-biotechnology-stocks-with-a-bright-future.html/?ref=YF
its website:
http://www.volitionrx.com/
tk
EAPH - gonna continue to move big
OCLG: MC 1.2 Mil. check ihub board http://investorshub.advfn.com/Oncologix-Tech-Inc-OCLG-21275/
TK
GNBT - Will be taking a look into this...Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer (SA article)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96212063
GNBT .045 Breast cancer preliminary data due Jan 31 2014. http://www.generex.com/news.php/news/817182 just found it. Lots of large blocks today. Isn't breast cancer huge?
Sure, good luck. I know he's been touting Ampligen for years now, but his clinical trial data is horrible, needa to set up better studies.
I understand. But even scam stocks in their sectors' time in the sun shoot way up. Examples are the coffee stock 2 years ago and the pot stocks now where there are only like 3 legit penny companies out there. Making a decision based on 1 doctor wouldn't do it for me. This Alferon/anti viral injection are in the spotlight imho. But thank you for your advice :)
I played HEB back in 2009. Since then I wouldn't touch it, JMO. I think Dr. Carter is nuts, and there's a lot of issues with the clinical trials for his super-drug. There's a lot better plays out there...
What do you guys think of HEB? looks to me like has gap to fill on the charts. I hear they also have a Barda grant in the works for some antivaral thing. H7N9 bird flu play
SVFC - stem cell biotech. Closed above the 50 day (MA) yesterday. Chart is ready!
IGXT - Can't wait to see this baby breaks .70- $0.72 then it takes off IMO.
ISR: MC 30Mil. FDA approved their liquid cesium products to treat certain types of brain cancer. Their other products also used to treat variety of cancers too. Undervalued currently, it should be at least $3 imho. Hidden Germ!
Check their website here: http://www.isoray.com
ELTP - Little chimpanzee is turning into a gorilla here.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95963534
Yep - nice consolidation day. Chart was overbought - needs to cool down a bit. Plenty of time to run before 2/3/14 PDUFA date
IGXT
IGXT did consolidated today. I added some more earlier.
I might have to get in on some LJPC here!
We'll let you slide since it's your first post here…..and you have a nice profile pic :)
Nice to see you ID Supermoney!
Does APPA still count after R/S today was at $0.44 now at $8.80 after??
ID
IGXT - NHOD @ .735!
IGXT - Awesomeee! Weeee we'll be @$1 no time here before Feb 3 IMO!
IGXT - new HOD up at .73!
IGXT - IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
Ref. http://finance.yahoo.com/news/intelgenx-announces-additional-development-commercialization-130500556.html
IGXT - nice news today. Also, upcoming PDUFA date in a few weeks...
IMUC looking good, nice pre-market activity
IMUC - WATCH it here! :)
IMUC - ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning
ref. http://finance.yahoo.com/news/immunocellular-therapeutics-issues-shareholder-letter-213800372.html
Report TOS
Yep - IGXT looks good Smurf.
IGXT - **ENTRY** @$0.58 - A little head-start here..I like to enter @$0.60-$0.62 but decided today to get in early...UPCOMING CATALYST - The migraine drug FDA approval date of (February 3, 2014) - 1/month PLAY here. Might go in and out but we'll see.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |